ClinicalTrials.gg
CompletedNCT05875701Updated Jun 26, 2025Results posted

Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA Vaccines

A Phase 3 interventional study of NVX-CoV2373 and SARS-CoV-2 rS antigen/Matrix-M Adjuvant in COVID-19, sponsored by Novavax. Completed at 5 sites in United States. Open to participants aged 18 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-26.

Sponsored by Novavax · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
147
Allocation
Randomized
Ages
18 Years to 49 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing NVX-CoV2373 adjuvated lipid nanoparticle in COVID-19 — none open to participants now, 2 under way, none of them phase 3. NVX-CoV2373 adjuvated lipid nanoparticle · COVID-19.

Enrollment
17th of 18
147 · median 997
Started
2023
with 3 others
Phase 3
7 of 18
none open now
Registered
11th of 18
by date
Lead sponsor
12 of 18
Novavax

Among the 18 studies testing NVX-CoV2373 adjuvated lipid nanoparticle in COVID-19, this one is the 17th largest by enrollment, is one of 4 that started in 2023, is one of 7 in phase 3, and was the 11th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

None of the 18 studies testing NVX-CoV2373 adjuvated lipid nanoparticle in COVID-19 is open now. The open studies under COVID-19, anywhere →

About NVX-CoV2373 adjuvated lipid nanoparticle

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 49 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing NVX-CoV2373 adjuvated lipid nanoparticle in COVID-19 as a file.
02

Study summary

This is an open-label Phase 3 study evaluating the immunogenicity and safety of Novavax vaccine(s) with Matrix-M™ adjuvant (ancestral strain NVX-CoV2373 and an alternative strain and/or multivalent Novavax vaccine) as booster doses following a series of primary and booster doses of authorized/approved mRNA vaccines followed by a single booster dose of NVX-CoV2373 in the Novavax 2019nCoV-307 study (NCT05463068).

Read the detailed description

This Phase 3 study investigates the immunogenicity and safety of Novavax's NVX-CoV2373 vaccine (including its Matrix-M adjuvant) as an additional booster dose for adults aged 18 to 49. Participants must have already received both their primary mRNA vaccine series and at least one booster dose of the same type. All participants were previously enrolled in Study 307 (NCT05463068), where they received either their primary mRNA vaccines with or without an additional mRNA booster, followed by a single NVX-CoV2373 booster.

The study involves up to 300 volunteers who will receive a single dose of the Novavax vaccine (5 micrograms of recombinant spike protein antigen and 50 micrograms of Matrix-M adjuvant) on Day 1.

03

Conditions studied

  • COVID-19

Browse trials for

04

Who can participate

Ages eligible
18 Years to 49 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

To be included in this study, each individual must satisfy all the following criteria:

  1. Adults 18 to 49 years (inclusive) of age at the time of vaccination in Study 307 who received two or three doses of mRNA prior to enrollment in Study 307, then one dose of ancestral strain NVX-CoV2373 in Study 307.
  2. Willing and able to give prior to study enrollment and to comply with study procedures.
  3. Participants of (defined as any participant who has experienced menarche and who is NOT surgically sterile [ie, hysterectomy, bilateral tubal ligation, or bilateral oophorectomy] or [defined as amenorrhea at least 12 consecutive months]) must agree to be heterosexually inactive from at least 28 days prior to enrollment and through the end of study (EOS) visit OR agree to consistently use a medically acceptable method of from at least 28 days prior to enrollment and through the EOS visit.
  4. Is medically stable, as determined by the investigator (based on review of health status, vital signs [to include body temperature], medical history, and physical examination [to include body weight]). Vital signs must be within medically acceptable ranges prior to the study vaccination.
  5. Agree to not participate in any other SARS-CoV-2 prevention or treatment trials for the duration of the study. Note: For participants who become hospitalized with COVID-19, participation in treatment studies is permitted.
  6. Documented receipt of COVID-19 vaccines. The most recent dose of NVX-CoV2373 must have been administered at least 180 days prior to vaccination in this study.

Exclusion criteria

Exclusion Criteria:

Participants meeting any of the following criteria will be excluded from the study.

  1. Received any additional COVID-19 vaccine booster after the Day 1 dose of NVX-CoV2373 administered during participation in Study 307.
  2. History of laboratory-confirmed (by polymerase chain reaction [PCR] or rapid antigen test) COVID-19 infection ≤ 4 months prior to Day 1.
  3. Current participation in research involving receipt of an product (drug/biologic/device).
  4. Any known allergies or history of anaphylaxis to the active substance or any of the other ingredients contained in the investigational product.
  5. Any or immunodeficiency disease/condition (iatrogenic or congenital) or therapy that causes .
  6. Received any vaccine ≤ 90 days prior to study vaccination, except for influenza vaccine which may be received > 4 days prior to study vaccine, or rabies vaccine, which may be received at any time if medically indicated.
  7. Received immunoglobulin, blood-derived products, or immunosuppressant drugs within 90 days prior to study vaccination, except for rabies immunoglobulin which may be given if medically indicated.
  8. Active cancer () on chemotherapy that is judged to cause significant immunocompromise within 1 year prior to first study vaccination (with the exception of malignancy cured via excision, at the discretion of the investigator).
  9. Participants who are breastfeeding, pregnant, or who plan to become pregnant prior to the EOS visit.
  10. Suspected or known history of alcohol abuse or drug addiction within 3 months prior to the study vaccine dose that, in the opinion of the investigator, might interfere with protocol compliance.
  11. Any other condition that, in the opinion of the investigator, would pose a health risk to the participant if enrolled or could interfere with evaluation of the trial vaccine or interpretation of study results (including neurologic or psychiatric conditions likely to impair the quality of safety reporting).
  12. Study team member or immediate family member of any study team member (inclusive of Sponsor, clinical research organization [CRO], and study site personnel involved in the conduct or planning of the study).
  13. Participants with a history of myocarditis or pericarditis.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
147 participants (actual)

Study arms

  • Experimental
    NVX CoV2373 (Ancestral strain)

    1dose of NVX-COV2373 on Day 1

    Biological: NVX-CoV2373

  • Experimental
    Updated COVID-19 Vaccine

    1dose of updated COVID-19 vaccine on Day 1

    Biological: SARS-CoV-2 rS antigen/Matrix-M Adjuvant

Interventions

  • BiologicalNVX-CoV2373

    1 intramuscular (IM) injection of 5 µg SARS-CoV-2 rS + 50 µg Matrix-M1 adjuvant (0.5 mL) given on Day 1

    Also known as: SARS-CoV-2 rS/Matrix-M Adjuvant

  • BiologicalSARS-CoV-2 rS antigen/Matrix-M Adjuvant

    1 intramuscular (IM) injection of 5 µg SARS-CoV-2 rS antigen+ 50 µg Matrix-M1 adjuvant (0.5 mL) given on Day 1

    Also known as: Updated Novavax COVID-19 vaccine

06

What researchers measure

Primary outcomes

  1. Neutralizing Antibody (Nab) for SARS-CoV-2 Wildtype Virus (Wuhan) Responses Expressed as Geometric Mean Titers (GMT)

    Neutralizing Antibody responses to ancestral strain Novavax vaccine (NVX-CoV2373) for the participants in the ancestral strain NVX-2373 group and NVX-CoV2540 group at Day 29

    Time frame: Day 28

Secondary outcomes

  1. Neutralizing Antibody (Nab) for SARS-CoV-2 Wildtype Virus (Wuhan) Responses Expressed as Seroconversion Rate (SCR)

    Neutralizing Antibody responses to ancestral strain Novavax vaccine (NVX-CoV2373) for the participants in the ancestral strain NVX-2373 group and NVX-CoV2540 group at Day 28

    Time frame: Day 28

  2. Serum Immunoglobulin G (IgG) ELISA Units to SARS-CoV-2 Spike Protein (Wuhan) Expressed as Geometric Mean ELISA Unit (GMEU)

    Serum Immunoglobulin G (IgG) ELISA Units to SARS-CoV-2 Spike Protein (Wuhan) in Ancestral strain NVX-CoV2373 group and updated NVX Vaccine group at Day 28

    Time frame: Day 28

  3. Serum Immunoglobulin G (IgG) ELISA Units to SARS-CoV-2 Spike Protein (Wuhan) Expressed as SCR

    Serum Immunoglobulin G (IgG) ELISA Units to SARS-CoV-2 Spike Protein (Wuhan) in Ancestral strain NVX-CoV2373 group and updated NVX Vaccine group at Day 28

    Time frame: Day 28

  4. Neutralizing Antibody Responses (Post-Booster) Expressed as GMT

    Post Booster Neutralizing Antibody responses GMTs compared with post-first booster results from Study 307

    Time frame: Day 0 and Day 28 of Study 307 and Study 312 (approximately 1 year from Day 0 of Study 307 and Day 0 of Study 312)

  5. Serum IgG Antibody Levels (Post-Booster) Expressed as GMEU

    Post Booster Serum IgG antibody levels expressed GMEUs compared with post-first booster results from Study 307

    Time frame: Day 0 and Day 28 of Study 307 and Study 312 (approximately 1 year from Day 0 of Study 307 and Day 0 of Study 312)

  6. Human Angiotensin-Converting Enzyme 2 (hACE2) Receptor Binding Inhibition Assay Expressed as SCR

    hACE2 Receptor Binding Inhibition Assay the SARS-CoV-2 ancestral strain spike protein expressed as SCR at Day 28

    Time frame: Day 28

  7. Number of Participants Reported Solicited Local and Systemic Adverse Events (AEs)

    Number of participants reported Solicited Local and Systemic Adverse Events (AEs) in the 7 days following study vaccination.

    Time frame: Day 7

  8. Number of Participants Reported With Medically Attended Adverse Events (MAAEs)

    Number of participants reported with Medically Attended Adverse Events (MAAEs) through Day 180 after the vaccine dose.

    Time frame: Day 180

  9. Number of Participants Reported With Serious Adverse Events (SAEs)

    Number of participants reported with Serious Adverse Events (SAEs) through Day 180 after the vaccine dose

    Time frame: Day 1 to Day 180

  10. Human Angiotensin-Converting Enzyme 2 (hACE2) Receptor Binding Inhibition Assay Expressed as SCR

    hACE2 Receptor Binding Inhibition Assay to the NVX-CoV2540(Updated COVID-19 Vaccine) expressed as SCR at Day 28

    Time frame: Day 28

07

Results

Posted Jun 26, 2025

Participant flow

Participant flow — Overall Study
MilestoneNVX CoV2373 (Ancestral Strain)NVX-CoV2540(Updated COVID-19 Vaccine)
Started10443
Completed10142
Not completed31
Withdrew: Lost to follow-up20
Withdrew: Withdrawal by subject11

Outcome measures

PrimaryNeutralizing Antibody (Nab) for SARS-CoV-2 Wildtype Virus (Wuhan) Responses Expressed as Geometric Mean Titers (GMT)

Neutralizing Antibody responses to ancestral strain Novavax vaccine (NVX-CoV2373) for the participants in the ancestral strain NVX-2373 group and NVX-CoV2540 group at Day 29

Time frame:
Day 28
Reported as:
Geometric mean · titers
Neutralizing Antibody (Nab) for SARS-CoV-2 Wildtype Virus (Wuhan) Responses Expressed as Geometric Mean Titers (GMT)
titersNVX CoV2373 (Ancestral Strain)NVX-CoV2540(Updated COVID-19 Vaccine)
Date of 1st booster dose (Study 307)173.2 (123.0 to 243.8)159.5 (94.3 to 269.9)
28 days after 1st booster dose (Study 307)396.6 (328.7 to 478.6)436.0 (305.6 to 622.2)
Date of 2nd booster dose (Study 312)306.4 (222.6 to 421.6)420.7 (282.5 to 626.6)
28 days after 2nd booster dose (Study 312)393.2 (318.0 to 486.2)835.0 (597.1 to 1167.6)
SecondaryNeutralizing Antibody (Nab) for SARS-CoV-2 Wildtype Virus (Wuhan) Responses Expressed as Seroconversion Rate (SCR)

Neutralizing Antibody responses to ancestral strain Novavax vaccine (NVX-CoV2373) for the participants in the ancestral strain NVX-2373 group and NVX-CoV2540 group at Day 28

Time frame:
Day 28
Reported as:
Number · participants
Neutralizing Antibody (Nab) for SARS-CoV-2 Wildtype Virus (Wuhan) Responses Expressed as Seroconversion Rate (SCR)
participantsNVX CoV2373 (Ancestral Strain)NVX-CoV2540(Updated COVID-19 Vaccine)
28 days after 1st booster relative to date of 1st booster2411
28 days after 2nd booster relative to date of 2nd booster2111
28 days after 2nd booster relative to date of 1st booster3122
SecondarySerum Immunoglobulin G (IgG) ELISA Units to SARS-CoV-2 Spike Protein (Wuhan) Expressed as Geometric Mean ELISA Unit (GMEU)

Serum Immunoglobulin G (IgG) ELISA Units to SARS-CoV-2 Spike Protein (Wuhan) in Ancestral strain NVX-CoV2373 group and updated NVX Vaccine group at Day 28

Time frame:
Day 28
Reported as:
Geometric mean · Elisa Units per mL
Serum Immunoglobulin G (IgG) ELISA Units to SARS-CoV-2 Spike Protein (Wuhan) Expressed as Geometric Mean ELISA Unit (GMEU)
Elisa Units per mLNVX CoV2373 (Ancestral Strain)NVX-CoV2540(Updated COVID-19 Vaccine)
Date of 1st booster dose (Study 307)37822.4 (29104.7 to 49151.4)32446.8 (22453.4 to 46888.0)
28 days after 1st booster dose (Study 307)93969.2 (79844.0 to 110593.4)93636.6 (69077.5 to 126927.1)
Date of 2nd booster dose (Study 312)67333.6 (54380.8 to 83371.6)71336.1 (50460.2 to 100848.6)
28 days after 2nd booster dose (Study 312)162144.7 (136476.6 to 192640.4)203864.0 (148535.6 to 279801.8)
SecondarySerum Immunoglobulin G (IgG) ELISA Units to SARS-CoV-2 Spike Protein (Wuhan) Expressed as SCR

Serum Immunoglobulin G (IgG) ELISA Units to SARS-CoV-2 Spike Protein (Wuhan) in Ancestral strain NVX-CoV2373 group and updated NVX Vaccine group at Day 28

Time frame:
Day 28
Reported as:
Number · participants
Serum Immunoglobulin G (IgG) ELISA Units to SARS-CoV-2 Spike Protein (Wuhan) Expressed as SCR
participantsNVX CoV2373 (Ancestral Strain)NVX-CoV2540(Updated COVID-19 Vaccine)
28 days after 1st booster relative to date of 1st booster2211
28 days after 2nd booster relative to date of 2nd booster2211
28 days after 2nd booster relative to date of 1st booster4522
SecondaryNeutralizing Antibody Responses (Post-Booster) Expressed as GMT

Post Booster Neutralizing Antibody responses GMTs compared with post-first booster results from Study 307

Time frame:
Day 0 and Day 28 of Study 307 and Study 312 (approximately 1 year from Day 0 of Study 307 and Day 0 of Study 312)
Reported as:
Geometric mean · geometric mean titer
Neutralizing Antibody Responses (Post-Booster) Expressed as GMT
geometric mean titerNVX CoV2373 (Ancestral Strain)
Day 0 of 1st booster dose (Study 307)173.2 (123.0 to 243.8)
28 days after 1st booster dose (Study 307)396.6 (328.7 to 478.6)
Day 0 of 2nd booster dose (Study 312)306.4 (222.6 to 421.6)
28 days after 2nd booster dose (Study 312)393.2 (318.0 to 486.2)
SecondarySerum IgG Antibody Levels (Post-Booster) Expressed as GMEU

Post Booster Serum IgG antibody levels expressed GMEUs compared with post-first booster results from Study 307

Time frame:
Day 0 and Day 28 of Study 307 and Study 312 (approximately 1 year from Day 0 of Study 307 and Day 0 of Study 312)
Reported as:
Geometric mean · geometric mean Elisa Units
Serum IgG Antibody Levels (Post-Booster) Expressed as GMEU
geometric mean Elisa UnitsNVX CoV2373 (Ancestral Strain)
Day 0 of 1st booster dose (Study 307)37822.4 (29104.7 to 49151.4)
28 days after 1st booster dose (Study 307)93969.2 (79844.0 to 110593.4)
Day 0 of 2nd booster dose (Study 312)67333.6 (54380.8 to 83371.6)
28 days after 2nd booster dose (Study 312)162144.7 (136476.6 to 192640.4)
SecondaryHuman Angiotensin-Converting Enzyme 2 (hACE2) Receptor Binding Inhibition Assay Expressed as SCR

hACE2 Receptor Binding Inhibition Assay the SARS-CoV-2 ancestral strain spike protein expressed as SCR at Day 28

Time frame:
Day 28
Reported as:
Number · Percentage of participants
Human Angiotensin-Converting Enzyme 2 (hACE2) Receptor Binding Inhibition Assay Expressed as SCR
Percentage of participantsNVX CoV2373 (Ancestral Strain)
Human Angiotensin-Converting Enzyme 2 (hACE2) Receptor Binding Inhibition Assay Expressed as SCR12.6 (5.9 to 21.2)
SecondaryNumber of Participants Reported Solicited Local and Systemic Adverse Events (AEs)

Number of participants reported Solicited Local and Systemic Adverse Events (AEs) in the 7 days following study vaccination.

Time frame:
Day 7
Reported as:
Count of participants · Participants
Number of Participants Reported Solicited Local and Systemic Adverse Events (AEs)
ParticipantsNVX CoV2373 (Ancestral Strain)NVX-CoV2540(Updated COVID-19 Vaccine)
Any solicited local reaction6831
Pain4818
Tenderness6229
Redness71
Swelling50
Systemic reaction6924
Fever11
Fatigue4911
Malaise315
Muscle pain4319
Joint pain197
Nausea/vomiting125
Headache4013
SecondaryNumber of Participants Reported With Medically Attended Adverse Events (MAAEs)

Number of participants reported with Medically Attended Adverse Events (MAAEs) through Day 180 after the vaccine dose.

Time frame:
Day 180
Reported as:
Count of participants · Participants
Number of Participants Reported With Medically Attended Adverse Events (MAAEs)
ParticipantsNVX CoV2373 (Ancestral Strain)NVX-CoV2540(Updated COVID-19 Vaccine)
MAAEs51
Severe MAAEs01
SecondaryNumber of Participants Reported With Serious Adverse Events (SAEs)

Number of participants reported with Serious Adverse Events (SAEs) through Day 180 after the vaccine dose

Time frame:
Day 1 to Day 180
Reported as:
Count of participants · Participants
Number of Participants Reported With Serious Adverse Events (SAEs)
ParticipantsNVX CoV2373 (Ancestral Strain)NVX-CoV2540(Updated COVID-19 Vaccine)
Number of Participants Reported With Serious Adverse Events (SAEs)01
SecondaryNeutralizing Antibody Responses (Post-Booster) Expressed as GMT

Post Booster Neutralizing Antibody responses GMTs compared with post-first booster results from Study 307

Time frame:
Day 0 and Day 28 of Study 307 and Study 312 (approximately 1 year from Day 0 of Study 307 and Day 0 of Study 312)
Reported as:
Geometric mean · geometric mean titer
Neutralizing Antibody Responses (Post-Booster) Expressed as GMT
geometric mean titerNVX-CoV2540(Updated COVID-19 Vaccine)
Day 0 of 1st booster dose (Study 307)159.5 (94.3 to 269.9)
28 days after 1st booster dose (Study 307)436.0 (305.6 to 622.2)
Day 0 of 2nd booster dose (Study 312)420.7 (282.5 to 626.6)
28 days after 2nd booster dose (Study 312)835.0 (597.1 to 1167.6)
SecondarySerum IgG Antibody Levels (Post-Booster) Expressed as GMEU

Post Booster Serum IgG antibody levels expressed GMEUs compared with post-first booster results from Study 307

Time frame:
Day 0 and Day 28 of Study 307 and Study 312 (approximately 1 year from Day 0 of Study 307 and Day 0 of Study 312)
Reported as:
Geometric mean · geometric mean Elisa Units
Serum IgG Antibody Levels (Post-Booster) Expressed as GMEU
geometric mean Elisa UnitsNVX-CoV2540(Updated COVID-19 Vaccine)
Day 0 of 1st booster dose (Study 307)32446.8 (22453.4 to 46888.0)
28 days after 1st booster dose (Study 307)93636.6 (69077.5 to 126927.1)
Day 0 of 2nd booster dose (Study 312)71336.1 (50460.2 to 100848.6)
28 days after 2nd booster dose (Study 312)203864.0 (148535.6 to 279801.8)
SecondaryHuman Angiotensin-Converting Enzyme 2 (hACE2) Receptor Binding Inhibition Assay Expressed as SCR

hACE2 Receptor Binding Inhibition Assay to the NVX-CoV2540(Updated COVID-19 Vaccine) expressed as SCR at Day 28

Time frame:
Day 28
Reported as:
Number · participants
Human Angiotensin-Converting Enzyme 2 (hACE2) Receptor Binding Inhibition Assay Expressed as SCR
participantsNVX-CoV2540(Updated COVID-19 Vaccine)
Human Angiotensin-Converting Enzyme 2 (hACE2) Receptor Binding Inhibition Assay Expressed as SCR1

Adverse events

Collected over 6 months. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
NVX CoV2373 (Ancestral Strain)0/104 (0%)0/104 (0%)2/104 (1.9%)
NVX-CoV2540(Updated COVID-19 Vaccine)0/43 (0%)1/43 (2.3%)1/43 (2.3%)
Most frequent serious events
Most frequent serious events
EventNVX CoV2373 (Ancestral Strain)NVX-CoV2540(Updated COVID-19 Vaccine)
Post procedural haematomaInjury, poisoning and procedural complications0/1041/43
Most frequent other events
Most frequent other events
EventNVX CoV2373 (Ancestral Strain)NVX-CoV2540(Updated COVID-19 Vaccine)
LymphadenopathyBlood and lymphatic system disorders0/1041/43
COVID-19Infections and infestations2/1040/43

Baseline characteristics

Safety Analysis Set

Age, Continuous
Age, Continuous(years)NVX CoV2373 (Ancestral Strain)NVX-CoV2540(Updated COVID-19 Vaccine)Total
Mean38.3 ± 7.9737.2 ± 9.2037.75 ± 8.58
Sex: Female, Male
Sex: Female, Male(Participants)NVX CoV2373 (Ancestral Strain)NVX-CoV2540(Updated COVID-19 Vaccine)Total
Female632386
Male412061
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)NVX CoV2373 (Ancestral Strain)NVX-CoV2540(Updated COVID-19 Vaccine)Total
Hispanic or Latino12618
Not Hispanic or Latino9236128
Unknown or Not Reported011
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)NVX CoV2373 (Ancestral Strain)NVX-CoV2540(Updated COVID-19 Vaccine)Total
White732598
Black or African American231538
Asian336
Other303
Not Reported/Specified202
Time between first dose of previous NVX vaccine at Study 307 and Day 1 dose of Study 312
Time between first dose of previous NVX vaccine at Study 307 and Day 1 dose of Study 312(days)NVX CoV2373 (Ancestral Strain)NVX-CoV2540(Updated COVID-19 Vaccine)Total
Mean265.0 ± 25.92311.0 ± 1.85288 ± 27.77
PCR, n (%)
PCR, n (%)(Participants)NVX CoV2373 (Ancestral Strain)NVX-CoV2540(Updated COVID-19 Vaccine)Total
Positive101
Negative9842140
Missing516
08

Study locations

5 sites
  • Benchmark Research
    Austin, Texas 78705, United States
  • Tekton Research
    Austin, Texas 78747, United States
  • Benchmark Research
    Fort Worth, Texas 76135, United States
  • Research Your Health
    Plano, Texas 75093, United States
  • Tekton Research
    San Antonio, Texas 78229, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2023 to primary completion in Nov 2023, 7 months.

Results were first posted in Jun 2025, 1 year 7 months after primary completion. A results delay was requested in Feb 2024.

Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 7 months is below that.

Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2023
First posted
May 25, 2023
StartActual
Mar 28, 2023
Primary completionActual
Nov 11, 2023
CompletionActual
Nov 11, 2023
Results delay requested
Feb 16, 2024
Results first posted
Jun 26, 2025
Last update
Jun 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05875701
Lead sponsor
Novavax
Responsible party
Sponsor
First posted
May 25, 2023
Start date
Mar 28, 2023
Primary completion
Nov 11, 2023
Completion
Nov 11, 2023
Results posted
Jun 26, 2025
Last update
Jun 26, 2025

Study contacts

Clinical Development
study director · Novavax, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: NVX-CoV2373 adjuvated lipid nanoparticle

Start the discussion